Diana Chirovsky

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&amp;N study

Viktor Grünwald, Diana Chirovsky, Winson Y. Cheung et al. · Oral Oncology · 2020 · 52 citations · Full text

Medicine, Oncology, Chemotherapy +15

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective

Ishan Hirji, Shaloo Gupta, Amir Goren et al. · Health and Quality of Life Outcomes · 2013 · 49 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

Danny Rischin, Kevin J. Harrington, Richard Greil et al. · Oral Oncology · 2022 · 42 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data

Howard West, Xiaohan Hu, Su Zhang et al. · Clinical Lung Cancer · 2022 · 42 citations · Full text

Medicine, Oncology, Surgery +12